Opendata, web and dolomites


Therapeutic approaches to enhance innate immunity against Tumors

Total Cost €


EC-Contrib. €






 TNT-TUMORS project word cloud

Explore the words cloud of the TNT-TUMORS project. It provides you a very rough idea of what is the project "TNT-TUMORS" about.

interesting    never    completely    harness    cancer    independent    tumorigenic    molecular    therapies    look    drugs    immune    tumors    significance    metastasis    plan    tumor    subset    fight    patients    inhibitors    treatment    immunemodulatory    interaction    cells    molecularly    tumorigenesis    modulation    samples    inducible    mechanism    occurs    immunetherapy    genetic    poorly    cell    expressing    ensures    screens    cooperation    dissect    phenotype    platform    start    close    models    specificity    effect    reevaluate    mouse    tam    direct    mimicking    checkpoint    adaptive    fast    mechanisms    anti    shows    clinical    attack    types    therapeutic    innate    macrophages    plasmacytoid    tams    recent    dendritic    standard    vivo    translation    clinicians    killing    capacity    endowing    cancers    predictive    immunemodulation    possibility    instructed    rnai    recognition    human    utilize    first    validated    power    egfr    strategies    capacities    activated    restrained    pdcs    vitro   

Project "TNT-TUMORS" data sheet

The following table provides information about the project.


Organization address
address: SPITALGASSE 23
city: WIEN
postcode: 1090

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website
 Total cost 2˙499˙646 €
 EC max contribution 2˙499˙646 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-AdG
 Funding Scheme ERC-ADG
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2021-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) coordinator 2˙499˙646.00


 Project objective

Recent advances using immune checkpoint inhibitors demonstrate the great potential of immunemodulation in cancer and metastasis treatment. However, the effective treatment of only a subset of patients shows that this is only the start to utilize the power of the immune system to fight cancer. An interesting approach is to harness innate immune cells, such as plasmacytoid dendritic cells (pDCs) and tumor-associated macrophages (TAM) to attack tumors and to enhance the effect of standard anti-cancer therapies. Recently, using mouse models we identified two independent mechanisms by which modulation of these two cell types restrained tumor growth. First, the direct killing of tumor cells by pDCs that occurs independent of the adaptive immune system. Second, we identified a tumor-promoting role of EGFR-expressing (EGFR) TAMs during tumorigenesis. This enables us to look at the role of EGFR in tumorigenesis in a completely new way and we plan to exploit this novel finding to reevaluate the mechanism by which anti-EGFR drugs are effective in tumors. The mechanisms endowing pDCs with tumor-killing capacities and determining the specificity of tumor cell recognition by activated pDCs are poorly understood. Furthermore, the interaction of pDCs with macrophages has never been investigated in tumors. Here I propose to define the molecular mechanisms by which pDCs and TAMs can be instructed to adopt an anti-tumorigenic phenotype. Inducible and cell-specific genetic mouse models mimicking human cancers will allow to molecularly dissect the immunemodulatory capacity of pDCs and TAMs. State-of-the-art large scale in vitro and in vivo RNAi screens will provide a platform to identify novel molecular pathways and open the possibility for testing new strategies in cancer immunetherapy. The clinical significance of our findings will be validated in human cancer samples in close cooperation with clinicians, which ensures a fast predictive and therapeutic translation of our results.


year authors and title journal last update
List of publications.
2017 Sriram Srivatsa, Mariel C. Paul, Claudia Cardone, Martin Holcmann, Nicole Amberg, Paulina Pathria, Michaela A. Diamanti, Markus Linder, Gerald Timelthaler, Hans P. Dienes, Lukas Kenner, Fritz Wrba, Gerald W. Prager, Stefan Rose-John, Robert Eferl, Giuseppina Liguori, Gerardo Botti, Erika Martinelli, Florian R. Greten, Fortunato Ciardiello, Maria Sibilia
EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients
published pages: 178-190.e10, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2017.03.053
Gastroenterology 153/1 2020-04-08
2018 Markus Linder, Elisabeth Glitzner, Sriram Srivatsa, Latifa Bakiri, Kazuhiko Matsuoka, Parastoo Shahrouzi, Monika Dumanic, Philipp Novoszel, Thomas Mohr, Oliver Langer, Thomas Wanek, Markus Mitterhauser, Erwin F Wagner, Maria Sibilia
EGFR is required for FOS‐dependent bone tumor development via RSK2/CREB signaling
published pages: e9408, ISSN: 1757-4676, DOI: 10.15252/emmm.201809408
EMBO Molecular Medicine 10/11 2020-04-08
2018 Stefanie Schmidt, Neele Schumacher, Jeanette Schwarz, Simone Tangermann, Lukas Kenner, Michaela Schlederer, Maria Sibilia, Markus Linder, Annelore Altendorf-Hofmann, Thomas Knösel, Elisabeth S. Gruber, Georg Oberhuber, Julia Bolik, Ateequr Rehman, Anupam Sinha, Juliane Lokau, Philipp Arnold, Anne-Sophie Cabron, Friederike Zunke, Christoph Becker-Pauly, Adele Preaudet, Paul Nguyen, Jennifer Huynh, Shoukat Afshar-Sterle, Ashwini L. Chand, Jürgen Westermann, Peter J. Dempsey, Christoph Garbers, Dirk Schmidt-Arras, Philip Rosenstiel, Tracy Putoczki, Matthias Ernst, Stefan Rose-John
ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling
published pages: 1205-1225, ISSN: 0022-1007, DOI: 10.1084/jem.20171696
The Journal of Experimental Medicine 215/4 2020-04-08
2018 Markus Linder, Manfred Hecking, Elisabeth Glitzner, Karin Zwerina, Martin Holcmann, Latifa Bakiri, Maria Grazia Ruocco, Jan Tuckermann, Georg Schett, Erwin F. Wagner, Maria Sibilia
EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation
published pages: 1094-1106, ISSN: 1350-9047, DOI: 10.1038/s41418-017-0054-7
Cell Death & Differentiation 25/6 2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TNT-TUMORS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TNT-TUMORS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

CiliaCircuits (2020)

Molecular Principles of Mammalian Axonemal Dynein Assembly

Read More  

VIVA (2020)

Vaccine development against variable pathogens

Read More